Lixte Biotechnology Holdings Inc Quick Ratio (LIXT) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Lixte Biotechnology Holdings Inc   (NASDAQ: LIXT)

Lixte Biotechnology Holdings Inc 's Quick Ratio

LIXT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Lixte Biotechnology Holdings Inc 's Cash & cash equivalent grew by 289.77 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Lixte Biotechnology Holdings Inc 's Quick Ratio to 8.45, Quick Ratio remained below Lixte Biotechnology Holdings Inc average.

Within Major Pharmaceutical Preparations industry 125 other companies have achieved higher Quick Ratio than Lixte Biotechnology Holdings Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 549, from total ranking in the first quarter 2026 at 979.

Explain Quick Ratio?
How much Cash & cash equivalents LIXT´s has?
What are LIXT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LIXT Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 179.28 % 989.01 % 1501.86 % 615.2 % 308.63 %
Y / Y Cash & cash equivalent Change 1328.09 % 134.76 % 391.54 % 76.35 % -65.81 %
Quick Ratio MRQ 8.45 2.65 3.83 5.54 1.65
LIXT's Total Ranking # 549 # 979 # 0 # 518 # 1083
Seq. Current Liabilities Change 22.46 % -8.12 % 155.68 % -2.92 % 377.52 %
Seq. Cash & cash equivalent Change 289.77 % -36.35 % 76.84 % 225.5 % -35.93 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 126
Healthcare Sector # 195
Overall Market # 549


Quick Ratio Statistics
High Average Low
62.55 12.93 0.7
(Dec 31 2010)   (Mar 31 2014)




Financial Statements
Lixte Biotechnology Holdings Inc 's Current Liabilities $ 2 Millions Visit LIXT's Balance sheet
Lixte Biotechnology Holdings Inc 's Cash & cash equivalent $ 13 Millions Visit LIXT's Balance sheet
Source of LIXT's Sales Visit LIXT's Sales by Geography


Cumulative Lixte Biotechnology Holdings Inc 's Quick Ratio

LIXT's Quick Ratio for the trailling 12 Months

LIXT Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 468.37 % 804.03 % 368.71 % 106.34 % 6.56 %
Y / Y Cash & cash equivalent TTM Growth 383.29 % 82.27 % 18.2 % -47.69 % -67.7 %
Quick Ratio TTM 5.22 3.35 4.1 4.94 6.14
Total Ranking TTM # 3546 # 3013 # 2796 # 2996 # 2874
Seq. Current Liabilities TTM Growth 26.63 % 44.42 % 99.66 % 55.67 % 101.4 %
Seq. Cash & cash equivalent TTM Growth 97.12 % 18.17 % 65.63 % 25.27 % -25.66 %

Quick ratio ranking by company, industry and sector >> Back to LIXT Financial Strength Comparisons >> Go to Compare LIXT Quick Ratio to its Competitors

On the trailing twelve months basis LIXT Cash & cash equivalent more than doubled by 1328.09 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Lixte Biotechnology Holdings Inc 's Quick Ratio to 5.22, Quick Ratio remained below LIXT average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 421 other companies have achieved higher Quick Ratio than Lixte Biotechnology Holdings Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3013 to 3546.

Explain Quick Ratio?
How much Cash & cash equivalents LIXT´s has?
What are LIXT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 422
Healthcare Sector # 858
Within the Market # 3546


trailing twelve months Quick Ratio Statistics
High Average Low
23.37 7.55 1.96
(Sep 30 2021)   (Dec 31 2014)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Equillium Inc   23.07 $ 57.164  Millions$ 2.478  Millions
Relmada Therapeutics Inc  21.72 $ 217.731  Millions$ 10.023  Millions
Keros Therapeutics Inc   21.20 $ 257.606  Millions$ 12.153  Millions
Protagonist Therapeutics inc   21.05 $ 782.576  Millions$ 37.181  Millions
Stablecoin Development Corporation  20.76 $ 7.122  Millions$ 0.343  Millions
Rhythm Pharmaceuticals Inc   20.65 $ 596.183  Millions$ 28.868  Millions
Structure Therapeutics Inc   20.31 $ 1,342.700  Millions$ 66.113  Millions
Scynexis Inc   19.69 $ 114.696  Millions$ 5.825  Millions
Q32 Bio Inc   19.68 $ 106.270  Millions$ 5.401  Millions
Damora Therapeutics Inc   19.62 $ 540.515  Millions$ 27.550  Millions
Kairos Pharma Ltd   19.12 $ 5.067  Millions$ 0.265  Millions
Minerva Neurosciences Inc   19.02 $ 75.267  Millions$ 3.958  Millions
Abcellera Biologics Inc   18.05 $ 960.143  Millions$ 53.189  Millions
Sellas Life Sciences Group Inc   17.29 $ 138.443  Millions$ 8.006  Millions
Whitehawk Therapeutics Inc   17.17 $ 190.000  Millions$ 11.069  Millions
Forte Biosciences Inc   17.12 $ 347.331  Millions$ 20.289  Millions
Ovid Therapeutics Inc   17.01 $ 169.769  Millions$ 9.980  Millions
Bioage Labs Inc   16.59 $ 318.745  Millions$ 19.217  Millions
Olema Pharmaceuticals Inc   16.48 $ 873.571  Millions$ 53.014  Millions
Erasca Inc   16.41 $ 610.496  Millions$ 37.200  Millions
Janux Therapeutics Inc   16.14 $ 970.913  Millions$ 60.152  Millions
Edgewise Therapeutics inc   15.86 $ 460.709  Millions$ 29.042  Millions
Corvus Pharmaceuticals Inc   15.74 $ 215.200  Millions$ 13.672  Millions
Telomir Pharmaceuticals Inc   15.55 $ 5.170  Millions$ 0.332  Millions
Rapport Therapeutics Inc   15.34 $ 436.077  Millions$ 28.424  Millions
Lb Pharmaceuticals Inc  15.32 $ 369.576  Millions$ 24.128  Millions
Anixa Biosciences Inc   15.09 $ 26.330  Millions$ 1.745  Millions
Siga Technologies Inc  14.99 $ 117.584  Millions$ 7.845  Millions
Vyne Therapeutics Inc   14.87 $ 22.925  Millions$ 1.542  Millions
Alto Neuroscience Inc   14.64 $ 243.733  Millions$ 16.652  Millions

Date modified: 2026-09-12T06:13:08+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.